Clinakos

Oncologists Respond to Care Challenges Presented by COVID-19

Clinakos, COVID-19, commercial, Clinical Development, Clinical Trials, ASCO

Oncologists Respond to Care Challenges Presented by COVID-19

ASCO survey finds 60% of cancer clinical research programs halted screening and/or enrollment of clinical trials due to Covid-19 difficulties. Further, ASCO also finds Oncology practices reporting grave impact on their patients and their families. This is expected to have a wide ranging impact on how oncology drugs are developed and commercialized. Clinakos Inc. is supporting our pharmaceutical partners and patients with digital patient data and insight solutions to enable progress on development and commercialization virtually.

Scroll to Top

Connect with us